Valuation: Insmed Incorporated

Market Cap 28.63B 24.76B 23.13B 21.22B 39.9B 2,725B 40.54B 271B 106B 1,366B 108B 105B 4,515B P/E 2026 *
-79.2x
P/E 2027 * 129x
Enterprise Value 28B 24.22B 22.62B 20.75B 39.02B 2,665B 39.64B 265B 104B 1,336B 105B 103B 4,415B EV / Sales 2026 *
15.6x
EV / Sales 2027 * 9.54x
Free-Float
98.74%
Yield 2026 *
-
Yield 2027 * -
1 day-1.09%
1 week+32.96%
Current month+32.96%
1 month+16.18%
3 months+24.86%
6 months-12.52%
Current year-24.67%
1 week 96.42
Extreme 96.42
137.7
1 month 96.42
Extreme 96.42
137.7
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.21
Extreme 21.21
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap.
7/23/26 Fiscal year

Chief Executive Officer

32,100 0.0148%
7/9/26 Fiscal year

Chief Executive Officer

32,097 0.0148%
7/6/26 Fiscal year

Chief Technology Officer

36,906 0.0170%
Change 5-day change 1-year change 3-year change Capi.($)
-1.09%+32.96%+19.95%+499.45% 28.63B
+8.49%+20.55%+69.74%+109.30% 68.12B
+1.25%+2.44%+32.55%+72.63% 55.18B
+2.72%+3.41%-15.88%-4.90% 23.53B
+10.83%+18.38%+52.76%+4.58% 23.99B
+6.50%+7.56%+38.20%-21.33% 18.45B
-3.88%+16.98%+199.30%+354.30% 15.83B
+6.20%+11.51%+34.94%+681.88% 16.44B
+3.58%+1.96%+44.61%+167.01% 13.4B
+2.12%+3.54%+445.77%+184.49% 12.38B
Average +3.67%+10.87%+92.19%+204.74% 27.59B
Weighted average by Cap. +4.26%+12.67%+67.26%+169.21%

Financials

2026 *2027 *
Net sales 1.79B 1.55B 1.45B 1.33B 2.5B 171B 2.54B 16.99B 6.67B 85.51B 6.73B 6.58B 283B 2.88B 2.49B 2.33B 2.13B 4.01B 274B 4.08B 27.28B 10.71B 137B 10.81B 10.57B 454B
Net income -344M -297M -278M -255M -479M -32.7B -486M -3.26B -1.28B -16.39B -1.29B -1.26B -54.19B 173M 150M 140M 129M 242M 16.51B 246M 1.64B 645M 8.28B 651M 637M 27.36B
Net Debt -632M -547M -510M -468M -881M -60.13B -895M -5.99B -2.35B -30.14B -2.37B -2.32B -99.64B -1.16B -1B -934M -857M -1.61B -110B -1.64B -10.96B -4.3B -55.17B -4.34B -4.25B -182B
Logo Insmed Incorporated
Insmed Incorporated specializes in the research and development of drugs for the treatment of respiratory, immunological, inflammatory, neurological, and rare diseases. At the end of 2025, the group has two products in the commercialization phase: ARIKAYCE® for the treatment of lung infection caused by the Mycobacterium avium complex and BRINSUPRI® for the treatment of bronchiectasis (dilation of the bronchi) unrelated to cystic fibrosis. The United States account for 74.7% of net sales.
Employees
1,664
Date Price Change Volume
26-08-07 US$131.10 -1.09% 4,904,085
26-08-06 US$132.55 +33.86% 12,036,146
26-08-05 US$99.02 +0.27% 4,899,602
26-08-04 US$98.75 +0.30% 4,290,804
26-08-03 US$98.45 -0.15% 3,546,860
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
131.10USD
Average target price
200.14USD
Spread / Average Target
+52.66%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock